{"nctId":"NCT01120600","briefTitle":"A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)","startDateStruct":{"date":"2010-06-09","type":"ACTUAL"},"conditions":["Osteoporosis"],"count":294,"armGroups":[{"label":"Odanacatib 50 mg once weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Odanacatib","Dietary Supplement: Vitamin D3","Dietary Supplement: Calcium carbonate"]},{"label":"Placebo once weekly","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Odanacatib","Dietary Supplement: Vitamin D3","Dietary Supplement: Calcium carbonate"]}],"interventions":[{"name":"Odanacatib","otherNames":["MK-0822"]},{"name":"Placebo for Odanacatib","otherNames":[]},{"name":"Vitamin D3","otherNames":[]},{"name":"Calcium carbonate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is a male between 40 and 95 years of age\n* Has osteoporosis\n* Has anatomy suitable for dual energy x-ray absorptiometry (DXA) scan of the lumbar spine and and hip\n* Is ambulatory\n\nExclusion Criteria:\n\n* Is currently on oral bisphosphonates or other treatment for osteoporosis\n* Had previous hip fragility fracture and is a candidate for standard of care therapy\n* Has had a fragility fracture (vertebral or non-vertebral fractures indicating reduced bone strength) within 12 months\n* Has had more then one previous vertebral fracture\n* Has been diagnosed with metabolic bone disorder other than osteoporosis\n* Is Vitamin D deficient\n* Has a history of renal stones\n* Has active parathyroid disease\n* Has history of thyroid disease not well controlled by medication\n* Is diagnosed with secondary osteoporosis\n* Has a daily calcium intake of \\<1,200 mg and is unwilling to take study prescribed supplements or increase dietary intake, such that his daily calcium intake is at least 1200 mg\n* Has a history of malignancy â‰¤5 years prior to signing informed consent\n* Has been diagnosed with hypogonadism due to causes that affect multiple organ and body systems","healthyVolunteers":false,"sex":"MALE","genderBased":true,"minimumAge":"40 Years","maximumAge":"95 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 24","description":"Lumbar spine BMD was assessed by dual energy X-ray absorptiometry (DXA) at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.86","spread":null},{"groupId":"OG001","value":"1.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Total Hip BMD at Month 24","description":"Total hip BMD was assessed by DXA at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null},{"groupId":"OG001","value":"-0.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Femoral Neck BMD at Month 24","description":"Femoral Neck BMD was assessed by DXA at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Trochanter BMD at Month 24","description":"Trochanter BMD was assessed by DXA at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.77","spread":null},{"groupId":"OG001","value":"0.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Serum C-Telopeptides of Type 1 Collagen (s-CTx) at Month 24","description":"Serum samples were collected to evaluate biochemical markers for s-CTx, which were measured at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.07","spread":null},{"groupId":"OG001","value":"56.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Urine Collagen N-Telopeptide/Creatinine Ratio (U-NTx/Cr) at Month 24","description":"Urine samples were collected to evaluate biochemical markers for u-NTx/Cr, which were measured at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.43","spread":null},{"groupId":"OG001","value":"6.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (s-BSAP) at Month 24","description":"Serum samples were collected to evaluate biochemical markers for s-BSAP, which were measured at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.28","spread":null},{"groupId":"OG001","value":"2.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Serum N-Terminal Propeptides of Type I Collagen (s-P1NP) at Month 24","description":"Serum samples were collected to evaluate biochemical markers for s-P1NP, which were measured at Baseline and at Month 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.94","spread":null},{"groupId":"OG001","value":"5.06","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Treatment Due to an AE","description":"An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":146},"commonTop":["Nasopharyngitis","Back pain","Arthralgia","Influenza like illness","Pain in extremity"]}}}